Credit Suisse Ag Aldeyra Therapeutics, Inc. Transaction History

Credit Suisse Ag

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	SELL	$6.11 - $8.16 $61,546 - $82,195	-10,073 Reduced 15.67%	54,203 $362,000
Q2 2023 Aug 11, 2023	BUY	$7.11 - $11.89 $457,002 - $764,241	64,276 New	64,276 $539,000
Q2 2022 Aug 12, 2022	BUY	$2.43 - $4.85 $63 - $126	26 New	26 $0
Q2 2021 Aug 16, 2021	SELL	$10.44 - $14.85 $136,137 - $193,644	-13,040 Closed	0 $0
Q1 2021 May 14, 2021	BUY	$6.53 - $14.42 $85,151 - $188,036	13,040 New	13,040 $155,000

117

36.4M

196K

142K

Ticker ALDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,323,100
Market Cap $290M
Description
Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It al...

Get notified when there are updates to the investment portfolio of Credit Suisse Ag, based on Form 13F filings with the SEC.

Stay updated on Credit Suisse Ag with notifications on news.